Geron’s Potential Blockbuster Imetelstat Faces Unexpected AdComm In MDS

Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.